




ILCA Annual Conference **2025**


Hong Kong
19-21 November

国际肝癌协会 ILCA 2025年度会议



18 November
ILCA
Masterclass

FINAL PROGRAMME





PROGRAMME AT A GLANCE

Pre-Conference Masterclass | 18 November 2025
19th annual conference | 19-21 November 2025



TABLE OF CONTENTS

Letter of Welcome	3
Registration	4
Venue & Accomodation	4
Programme at the glance	5
Programme ILCA Pre conference Masterclass	6
› Tuesday, 18 th November 2025	6
Programme ILCA Annual Conference 2025 Programme	7
› Wednesday, 19 th November 2025	7
› Thursday, 20 th November 2025	10
› Friday, 21 st November 2025	12
ILCA Annual Conference Programme Committee	14
Floorplan	15
Practicalities	16
Sponsors, Media and other Partners	17
About ILCA	19
Industry Symposia	20



Dear ILCA members, colleagues and friends,

It is with great pleasure that I welcome you to Hong Kong and the 19th Annual Conference of the International Liver Cancer Association (ILCA).

This year marks a special milestone as ILCA returns to Asia for the first time since our memorable gathering in Seoul in 2017. The region's dynamic growth in liver cancer research and clinical innovation makes it a fitting host for our global community.

ILCA continues to be a multidisciplinary force committed to improving outcomes in liver cancer through research, education, and collaboration. Over the next few days, you will engage with cutting-edge developments in clinical and fundamental science, hear from international leaders, and participate in lively debates and tumour board discussions. Your insights and contributions are not only welcome—they are essential.

This year's conference also serves as a unique meeting point for sister societies and patient advocacy groups. In the spirit of cross-society collaboration, we are thrilled to host sessions with KLCA (Korean Liver Cancer Association), INASL (Indian National association for the studies of liver), CCF (cholangiocarcinoma Foundation), and CLCS (Chinese Liver Cancer society). In addition, patient groups such as UNITE and ILCM (International Liver cancer movement) will be actively participating in dedicated meetings and discussions, ensuring that the patient voice remains central to our mission.

We are especially proud to launch our new Mentorship Programme at this year's conference. Designed to foster meaningful connections between early-career professionals and seasoned experts, this initiative reflects ILCA's commitment to nurturing the next generation of liver cancer leaders. We warmly invite all attendees to get involved—whether as mentors or mentees—and help build a stronger, more connected ILCA community.

This outstanding programme has been curated by our dedicated Programme Committee, chaired by Amit Singal, with invaluable support from the ILCA office team. We also extend our heartfelt thanks to our sponsors and partners—your support makes this conference possible.

Liver cancer care is evolving rapidly, and ILCA remains at the forefront of this transformation. May this conference inspire new ideas, energise your work, and deepen our shared commitment to progress.

Enjoy the conference!

On Behalf of the ILCA Governing Board
Tim Meyer, ILCA President



Tim Meyer MD, PhD
ILCA President



Amit Singal, MD
ILCA Executive Secretary



REGISTRATION

Registration must be completed online at [Registration – ILCALive](#)

ILCA members benefit from special registration fees. If you'd like to become a member, simply sign up today and benefit from the many advantages and join the ILCA community.

Attendee Category	Super Early Bird (until 7 th of April)	Early Bird (until 29 th of May)	Regular Fee (until 17 th of November)	On-Site Fee (18 th to 21 st November)
ILCA Member	320	420	535	595
Non-Member	520	690	745	800
Student ILCA Member	165	180	215	240
Student Non-Member	206	227	265	290
Nurse / Pharmacist member	165	180	215	240
Nurse / Pharmacist non -member	206	227	265	290
Virtual only fee	258	280	370	370

VIRTUAL REGISTRATION:

UNABLE TO JOIN US IN HONG KONG?

Participate virtually in **ILCA25** and access sessions from the comfort of your own space. Please note that the sessions are not live streamed, but with the Virtual Pass you will have access to the recordings which will be available soon after the end of the Conference.

VENUE & ACOMMODATION

The venue for ILCA AC2025 is the [Hong Kong Ocean Park Marriott Hotel](#).

Please visit <https://ilcalive.org> for future information and for hotel reservations.

Through this website you can reserve, modify or cancel your reservations at any time and receive updated information about the event.

We look forward to seeing you!





PROGRAMME AT A GLANCE

Pre-Conference Masterclass | 18 November 2025

19th annual conference | 19-21 November 2025



Time	Tuesday - 18 November	Wednesday - 19 November	Thursday - 20 November	Friday - 21 November
08:30 - 08:45	PRE CONFERENCE Masterclass			
08:45 - 09:00				GUERBET Industry Symposium
09:00 - 09:15				
09:15 - 09:30				
09:30 - 09:45				
09:45 - 10:00			Translation session on HCC/CCA treatment -joint session with CCF	Surgery And Transplant Oncology- Joint Session With Clcs
10:00 - 10:15				
10:15 - 10:30				
10:30 - 10:45			Coffee Break & Networking	Coffee Break & Networking
10:45 - 11:00				
11:00 - 11:15		Opening Ceremony	ILCA Advocacy	Basic State of the Art
11:15 - 11:30		Advances In Systemic Therapy	"Presidential Address & Award Ceremony"	General Session 4 Surveillance and diagnosis
11:30 - 11:45				
11:45 - 12:00			General Session 2 Epidemiology, Staging and Prognosis	
12:00 - 12:15				Survivorship and patient-reported outcomes
12:15 - 12:30		Lunch & Meet the expert - Y-ILCA Roundtables	Roche Lunch Industry Symposium	EISAI Lunch Industry Symposium
12:30 - 12:45				
12:45 - 13:00				
13:00 - 13:15		ILCA Legacy Session	Surveillance Joint session with KLCA	DEBATES
13:15 - 13:30		General Session 1 Molecular Pathogenesis, Cell Biology and Translational Research and Poster blast	General Session 3 Therapy & Miscellaneous	"Diagnosis & Staging -Joint Session With Inasl"
13:30 - 13:45				
13:45 - 14:00				
14:00 - 14:15				
14:15 - 14:30		Coffee Break & Networking	Coffee Break & General Assembly (for members only)	Closing Address
14:30 - 14:45		Translation session on HCC/CCA risk and prevention	Tumor Board	
14:45 - 15:00				
15:00 - 15:15				
15:15 - 15:30				
15:30 - 15:45				
15:45 - 16:00				
16:00 - 16:15				
16:15 - 16:30				
16:30 - 16:40				
16:40 - 16:45				
16:45 - 17:00				
17:00 - 17:15				
17:15 - 17:30				
17:30 - 17:45				
17:45 - 18:00		Poster Tour		
18:00 - 18:15			AstraZeneca Industry Symposium	
18:15 - 18:30				
18:30 - 18:45				
18:45 - 19:00		Welcome reception		
19:00 - 19:15			Y -ILCA Masterclass	



ILCA PRE CONFERENCE MASTERCLASS

In line with our commitment to supporting the future generations of hepatology professionals, we're excited to invite junior doctors and early-career academics to our exclusive pre-conference masterclass.

Taking place just before our Annual Conference, this masterclass is perfect for young researchers looking to explore the latest breakthroughs in HCC, from radiological diagnosis to liver transplant, surgery, and systemic therapies.

Time	Title	Speakers
Session I: Latest update on the landscape of HCC - Chairs: Pierce Chow, Stephen Chan		
9:15-9:30am	Opening	Stephen Chan (Hong Kong SAR, China)
9:30-9:50am	Radiological diagnosis of HCC: What's new	Hanyu Jiang (China)
9:50-10:10am	Liver transplant and Surgery	Pierce Chow (Singapore)
10:10-10:30am	Updates on systemic therapy for HCC	Maria Reig (Spain)
10:30-11:00am	Q&A	
11:00-11:15am	Break	
Session II: Evolving practice and concept on HCC - Chairs: Stephen Chan, Kenneth Chok		
11:15-11:40am	How to run MDT effectively: Round-table discussion	Surgical: Kenneth Chok (Hong Kong SAR, China) and Pierce Chow (Singapore) Oncology/Hepatology: Maria Reig (Spain) and Hsu Chiun (Taiwan) Radiologist: Hanyu Jiang (China)
11:40-12:00n	Conversion therapy: Do we have consensus	Kenneth Chok (Hong Kong SAR, China)
12:00-12:20pm	How to start big-data research	Grace Wong (Hong Kong SAR, China)
12:20-12:40pm	Q&A	
12:40-2:00pm	Lunch	
Section III: Practical tips to develop your academic career - Chairs: Hsu Chiun, Landon Chan		
2:00-2:20pm	Understanding scientific data: What clinician should know?	Carmen Wong (Hong Kong SAR, China)
2:20-2:40pm	The life of a clinician-scientist	Takahiro Kodama (Japan)
2:40-3:00pm	Q&A	
3:10-3:30pm	Publication in high-impact journals	Stephen Chan (Hong Kong SAR, China)
3:30-4:00pm	Q&A & break	
4:00-4:20pm	Academic presentation: The art and science	Hsu Chiun (Taiwan)
4:20-4:40pm	Understanding the terminology and modality of radiation	Landon Chan (Hong Kong SAR, China)
4:40-5:00pm	Q&A	
5:00-5:15pm	Closing Pre-Conference Masterclass	Hsu Chiun (Taiwan) and Pierce Chow (Singapore)

Thank you to our ILCA Pre-Conference Masterclass Sponsors





SCIENTIFIC PROGRAMME

DAY 1 | WEDNESDAY, 19TH NOVEMBER 2025

11:00 – 11:15	ILCA AC2025 Opening Ceremony Tim Meyer, ILCA President, MD, PhD, (UK)
11:15 – 13:00	Advances In Systemic Therapy & Encore Presentations 11.15 – 11.20 Introduction from session chairs Lorenza Rimassa, MD (Italy) Antonio d'Alessio, PhD (UK) 11.20 – 11.30 Antonio d'Alessio, PhD (UK) Neoadjuvant immunotherapy for HCC: how to move the field forward 11.30 – 11.40 Stephen Chan, MD, PhD, FAHA (Hong Kong SAR, China) Novel systemic therapy for HCC 11.40 – 11.50 Riad Salem, MD (USA) The future of LRT in the era of combination therapy 11.50 – 12.00 Lorenza Rimassa, MD (Italy) Systemic therapy for CCA: Today & Tomorrow 12.00 – 12.10 Questions & answers Encore Presentations 12.10 – 12.20 Stephen Chan, MD, PhD, FAHA (Hong Kong SAR, China) 0-17, Analysis of participants (pts) who were at risk of vascular endothelial growth factor inhibitor (VEGFi) side effects from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) 12.20 – 12.30 Jia-Yong Su, (China) 0-18, Target Trial Emulation of Adjuvant PD-1 Inhibitors ± Molecularly Targeted Agents Versus Active Surveillance in Resected Hepatocellular Carcinoma That Exceeds Up-to-7 Criteria 12.30 – 12.40 Xiaodong Wang, (China) 0-19, Prospective Multicentre Trial of Biliary Drainage Plus Hepatic Arterial Infusion Chemotherapy Versus Biliary Drainage Plus Best Supportive Care in Locally Advanced Perihilar Cholangiocarcinoma (DRAIC trial) 12.40 – 13.00 Questions & answers
13:00 – 14:00	Lunch



SCIENTIFIC PROGRAMME

DAY 1 | WEDNESDAY, 19TH NOVEMBER 2025

13.30 – 14.00	Y-ILCA Career Development Roundtables, session organised by the Y-ILCA Committee Chairs: Antonio d'Alessio, PhD (UK) Ryan Poting Iin, MD (Taiwan) Experts for Basic Science & Translational Research Daniela Sia, MD (USA) Valerie Chew, MD, PhD (Singapore) Experts for Clinical Chiara Braconi, MD, PhD (UK) Stephen Chan, MD, PhD, FAHA (Hong Kong SAR, China)
14.00 – 14.30	ILCA Legacy Session: Past, Present and Future Chair: Tim Meyer, MD, PhD, ILCA Actual President (UK) ILCA Founding Board and first ILCA President Jordi Bruix, MD (Spain) ILCA Past President Richard Finn, MD (USA) ILCA Past President Jessica Zucman-Rossi, MD (France) ILCA President Elect Stephen Chan, MD, PhD, FAHA (Hong Kong SAR, China)
14.30 – 16.00	General Session 1 - Molecular Pathogenesis, Cell Biology and Translational Research and Poster blast Chairs: Jesper Andersen (Denmark) Jessica Zucman-Rossi (France) 4 oral presentations from ILCA AC2025 accepted abstracts 0-1. Adaptive NK cell signature predicts outcomes in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab, Zhongguo Zhou (UK) 0-3. Spatial profiling of hepatocellular carcinoma identifies distinct tumor and immune micro-ecosystems related to patient outcomes, Qinghe Zeng (Germany) 0-2. Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypes, Long Pan (France) 0-4. Neoadjuvant Treatment Followed by Surgery Versus Upfront Surgery for Intrahepatic Cholangiocarcinoma: An International Multicenter Cohort Study, Anudari Zorigtbaatar (Canada) 8 Poster Blasts - 8 selected poster presenters will introduce their poster in «3 minutes pitch». P-14. Overall survival among 4913 patients with hepatocellular carcinoma treated with external beam radiation therapy: individual patient data outcomes from a multinational cohort, Andrew Moon (USA) P-1. Molecular-based therapies for primary liver cancers: real-world data from 120 patients of the 2025 French Genomic Medicine Initiative, Claudia Campani (France) P-11. Updated Prospective Analysis of Hepatic and Extrahepatic Cancer Risk in Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir: Insights from the SAINT Cohort, Sung-Eun Kim (Republic of Korea) P-4. Charting single-cell metabolism co-evolution during metastasis, Yingcheng Wu (China) P-7. Phenotypic variation in circulating neutrophils predicts response to trans-arterial chemoembolization in patients with HCC, Salem Nizami (UK) P-2. Molecular characterization of hemochromatosis related hepatocellular carcinomas, Long Pan (France) P-3. Replication Stress Stratifies HCC Aggressiveness and Predicts ATR Inhibitor Sensitivity, Jing Fang (France) P-10. Early Nivolumab addition to Regorafenib in patients with Hepatocellular Carcinoma after first-line therapy (GOING trial), Marco Sanduzzi (Spain)



SCIENTIFIC PROGRAMME

DAY 1 | WEDNESDAY, 19TH NOVEMBER 2025

16:00 - 16:30	Coffee Break & Networking
16.30 – 17.30	Translation session on HCC/CCA risk and prevention Chairs: Shishir Shetty, FRCP PhD (UK) Carmen Wong, MD (Hong Kong SAR, China) Multimomics stratification of HCC towards biomarkers discovery Irene Ng, MD (Hong Kong SAR, China) Translational breakthroughs for HCC treatment and prevention (TBC) Alfred Cheng, MD (Hong Kong, SAR, China) New insights in risk and prevention of CCA Sumera Ilyas, MD (USA) Genetic mutations that predispose to CCA Jessica Zucman-Rossi, MD (France)
17:30 – 18:15	Poster Tour Presentation of the best top posters <u>Basic Poster Tour Chairs:</u> Josep Maria Argemi, MD, (Spain) Anna Kwong, PhD, (Hong Kong SAR, China) <u>Basic Poster Tour Chairs:</u> Marco Sanduzzi, MD, (Spain) Nguyen Tran, MD, (USA)
18:15 – 19:15	Welcome Reception Join us for the welcome reception, where we will celebrate this year conference, connect with peers and thanks sponsors



SCIENTIFIC PROGRAMME

DAY 2 | Thursday, 20th November 2025

09.30 – 10.30	Translation session on HCC/CCA treatment - joint session with CCF (Cholangiocarcinoma Foundation)  Cholangiocarcinoma Foundation* 09.30 – 09.32 Introduction from session chairs Valerie Chew, MD, PhD (Singapore) Daniela Sia, MD (USA) 09.32 - 09.44 New systemic therapy landscapes for BTC (focus on translational) Chiara Braconi, MD, PhD (UK) 09.44 - 09.56 Organoids and translational models of iCCA Daniela Sia, MD (USA) 09.56 - 10.08 Immune Microenvironment of HCC: Interplay Between Cytokines and immune cells Anna Kwong, PhD (Hong Kong, SAR, China) 10.08 - 10.20 Immune Cells as Predictive Biomarkers for Immunotherapy Response in HCC and CCA Gao Qiang, MD, PhD (China) 10.20 - 10.30 Questions & answers
10.30 – 11.00	Coffee Break & Networking
11.00 – 11.30	ILCA Advocacy: Empowerment of Patients in multidisciplinary teams Chairs: Manon Allaire, Dr (France) Ken Lui, MD (Australia) 11.00 - 11.10 Ken Wong, MD (Hong Kong SAR, China) 11.10 - 11.20 Chan Leong Tat, MD (Hong Kong SAR, China) 11.20 - 11.30 Neus Llarch (Spain)
11.30 – 12.00	Presidential Address and Awards Ceremony · Nelson Fausto Award Announcement · Junior investigator Awards: · Best oral presentation (clinical) · Best oral presentation (basic/translational) · Best poster (clinical) · Best poster (basic/translational) In this session the International Liver Cancer Association is going to recognize 4 individuals for their outstanding contributions to advancing liver cancer research, Junior Investigator Awards as well as recognize this year Nelson Fausto Award.
12.00 – 13.00	General Session 2: Epidemiology, Staging and Prognosis Chairs: Gerda Elisabeth Villadsen (Denmark) Andrew Moon (USA) 4 oral presentations from ILCA AC25 accepted abstracts. 0-5. Prognostic significance of pretreatment 18F-FDG PET-CT in patients with hepatocellular carcinoma: a systematic review and meta-analysis, JI HYE MIN (Republic of Korea) 0-7. AFP-PIVKA-ALBI (APA) Score: A New Prognostic Tool for Patients with HCC Receiving Atezolizumab-Bevacizumab, Claudia Campani (France) 0-8. Early Diagnosis of hepatocellular carcinoma Relies Solely on Surveillance: Insights from the Social-CHIEF Study, Charlotte Costentin (France) 0-6. Long-Term Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Direct Acting Antivirals: Up to 8 Years, Jeong Han Kim (Republic of Korea)



SCIENTIFIC PROGRAMME

DAY 2 | Thursday, 20th November 2025

13.00 – 14.00	Roche Lunch Industry Symposium (see programme on page 18)
14.00 – 15.00	Surveillance - Joint session with KLCA (Korean Liver Cancer Association)  THE KOREAN LIVER CANCER ASSOCIATION 14.00 – 14.02 Introduction from session chairs Neehar Parikh, MD, MS (USA) June Sung Lee, MD (Republic of Korea) 14.02 -14.14 Risk stratification in patients undergoing surveillance: Anything ready for prime time in 2025? Pierre Nahon, MD (France) 14.14 - 14.26 Emerging imaging-based strategies for HCC surveillance So Yeon Kim, MD (Republic of Korea) 14.26 - 14.38 Role for CCA surveillance Shahid A Khan, MD (UK) 14.38 - 14.50 Emerging biomarker panels for HCC surveillance Soon Sun Kim, MD, PhD (Republic of Korea) 14.50 - 15.00 Questions & answers
15.00 – 16.00	General Session 3: Therapy & Miscellaneous Chairs: David Pinato (UK) Joycelyn Lee (Singapore) 4 oral presentations from ILCA AC2025 accepted abstracts. 0-16. Multicenter phase 2 trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04): final result, Changhoon Yoo (Republic of Korea) 0-13. TALENTACE: safety results from a phase III, multicenter, open-label, randomized trial of on-demand TACE combined with Atezolizumab+bevacizumab versus TACE alone in patients with systemically untreated, intermediate- to high-burden unresectable HCC, Masatoshi Kudo (Japan) 0-15. Prognostic Genomic Landscapes in Biliary Tract Cancer: A Pathway-Based Analysis of Molecular Interactions and Survival Outcomes from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Survival Outcomes from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab, Margherita Rimini (Italy) 0-14. Unique patterns of responders to atezolizumab + bevacizumab in advanced HCC as per spatial transcriptomics analysis, Marta Piqué-Gili (Spain)
16.00 – 16.45	Coffee Break & Networking General Assembly (Members only)
16.45 – 17.45	Tumor Board Chairs: Neil Mehta, MD, (USA) & Grainne O'Kane, MD (Ireland) Anjana Pillai, MD (USA) David Pinato, MD, PhD (UK) Edward Kim, MD (USA) Tiffany Wong, MD (Hong Kong SAR, China) Gonzalo Sapisochin, MD, PhD, MSc (Spain) Chairs will present a selection of relevant tumour board cases for the experts to review and provide valuable input and feedback on the recommended treatment approaches.
17.45 – 18.45	AstraZeneca Industry Symposium (see programme on page 18)
18.45 – 19.15	Y-ILCA Masterclass - How to publish our paper on a high-impact journal: tips from the editor. Session organised by the Y-ILCA Committee with the aim of helping young investigators improve their academic and research skills and broaden their academic network How to publish your paper on a high-impact journal: tips from the editor Chairs: Joycelyn Lee, MD (Singapore) and Ryan Poting Lin, MD (Taiwan) Jessica Zucman Rossi, MD (France) Masatoshi Kudo, MD, PhD (Japan)



SCIENTIFIC PROGRAMME

DAY 3 | Friday, 21st November 2025

08.30 – 09.30	GUERBET Industry Symposium (see programme on page 19)
09.30 – 10.30	Surgery and Transplant Oncology - Joint Session With CLCS (China Anti-Cancer Association Liver Cancer)  中国抗癌协会 CHINA ANTI-CANCER ASSOCIATION Introduction from session chairs Gonzalo Sapisochin, MD, PhD, MSc (Spain) and Ming Kuang, MD, PhD (China) 09.30- 09.42 Update on criteria for resectability of HCC and CCA Gonzalo Sapisochin, MD, PhD, MSc (Spain) 09.42 -09.54 Neoadjuvant and adjuvant therapies for HCC - what the future holds - ? Ming Kuang, MD, PhD (China) 09.54 -10.06 Update on Transplant for malignancies other than HCC - CRC mets and CCA - ? Karim Halazum, MD (USA) 10.06 -10.18 Downstaging for HCC - is there a limit? Huichuan Sun, Dr (China) 10.18 -10.30 Questions & Answers
10.30 – 11.00	Coffee Break & Networking
11.00 – 11.30	Basic State of the Art Senescence in HCC Chair: Valerie Chew, MD, (Singapore) Michael Karin, MD, PhD (USA)
11.30 – 12.30	General Session 4: Surveillance and Diagnosis Chairs: Julien Calderaro, PhD, MCU-PH (France) Su Jong Yu, MD, PhD (Republic of Korea) 4 oral presentations from ILCA AC2025 accepted abstracts. 0-9 Non-invasive detection and prediction of esophageal varices and liver decompensation events in AtezoBev-treated HCC patients through machine and foundation-model deep learning, Asier Rabasco (Germany) 0-10. Non-Invasive Detection and Monitoring of Liver Cancer Using Fragment-Level Cell-Free DNA Profiling, Bianca Kirsh (Canada) 0-11. A Machine Learning Model for Predicting Hepatocellular Carcinoma in Patients with MASLD, Han Ah Lee (Republic of Korea) 0-12. Aberrant lipid metabolism mediated by Elovl1 drives tumor–microenvironment, Zheng Jian (Hong Kong SAR, China)
12.30 – 13.15	Survivorship and patient-reported outcomes Introduction from session chairs Maria Reig, MD, PhD (Spain) Joong-Won Park, MD (Republic of Korea) 12:30 -12:40 Evidence based practice for palliative care for Liver Cancer Ken Liu, MD (Australia) 12:40 - 12:50 Caring Beyond Cure: The Vital Role of Nurses in Long-Term Survivorship Neus Llarch (Spain) 12.50 -13.00 Liver Cancer and Chroni IRAE: Navigating the therapeutic Tightrope Jean Charles Nault, MD (France) 13.00 – 13.15 Roundtable discussion



SCIENTIFIC PROGRAMME

DAY 3 | Friday, 21st November 2025

13.15 – 14.15	EISAI Lunch Industry Symposium (see programme on page 19)
14.15 – 15.00	ILCA Debates 14.15 -14.17 Introduction from session chairs Sumera Ilyas, MD, (USA) Jean charles Nault, MD, (France) Clinical debate: Patients with Vp1/2 should be treated with locoregional/surgical therapies Neehar Parikh, MD, MS (USA) Clinical debate: Patients with Vp1/2 should be treated with systemic therapies David Pinato, MD, PhD, (UK) Basic Science Debate: AI will become the PI (against) Carmen Wong, MD (Hong Kong SAR, China) Basic Science Debate: AI will become the PI (for) Julien Calderaro, PhD, MCU-PH (France)
15.00 – 16.10	DIAGNOSIS & STAGING -joint session with INASL (India National Association for Study of the Liver)  15.00 -15.02 Introduction from session chairs Neil Mehta, MD (USA) Anjana Pillai, MD (USA) 15.02 - 15.17 Pathological Diagnosis of HCC Valerie Paradis, MD, PhD (France) 15.17 -15.37 Novel PET Modalities in HCC Anand Kulkarni, MD, FACC (India) 15.37 – 15.57 Biomarkers in HCC Ashish Kumar, MD, PhD (India) 15.57 – 16.07 Prognostic and predictive value of imaging biomarkers Julius Chapiro, MD, PhD (USA)
16.30 – 16.40	Closing Address Tim Meyer, ILCA President, MD (UK)





ILCA ANNUAL CONFERENCE PROGRAMME COMMITTEE

A Big Thank You to the Members of ILCA AC2025 Programme Committee
for taking time out of their busy schedules to plan, organise and oversee the scientific programme.
Their work and energy are making a difference at this year annual conference.



Amit Singal
Programme Committee Chair
USA



Manon Allaire
France



Stephen Chan
Hong Kong SAR, China



Valerie Chew
Singapore



Antonio D'Alessio
UK



Masatoshi Kudo,
Japan



Amaia Lujambio
USA



Jeong Min Lee
Republic of Korea



Kuang Min
China



Anjana Pillai
USA



Maria Reig
Spain



Gonzalo Sapisochin
Spain



Su Jong Yu
Republic of Korea



Carmen Wong
Hong Kong SAR, China





Pre-Conference Masterclass | 18 November 2025
19th annual conference | 19-21 November 2025

The floor plan illustrates the layout of the exhibition hall, including the following details:

- Booths:** 10 numbered booths are arranged in a grid. Booths 1 and 2 are large yellow rectangular booths at the bottom. Booths 3-10 are smaller blue rectangular booths arranged in two rows of five. Dimensions for each booth are provided (e.g., Booth 1: 6mL x 3mW, Booth 3: 3mL x 3mW).
- Meeting Rooms:** Meeting Room 1 and Meeting Room 2 are located on the left side of the hall.
- Ballroom 3:** A large rectangular area at the top right, separated from the main hall by a dashed line.
- Other Features:** A Storage area is located at the bottom right. A Lift is indicated on the left side. A Control Panel and Moderator area are located on the right side. Build-in Screens and a Build-in LED Wall are also shown.
- Entrances:** The main entrance is at the bottom left, with a red arrow indicating the direction of flow. A secondary entrance is at the top left, with a blue arrow indicating the direction of flow.



PRACTICALITIES

About the Conference

The International Liver Cancer Association (ILCA) is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines.

ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver cancer through the enhancement of the knowledge of clinical, translational and basic research, creating novel preventive, diagnostic and therapeutic strategies. The purpose for which ILCA was established is the advancement of medical education, research, and clinical care in the field of liver cancer. More ILCA Information is also available at www.ilca-online.org.

Accreditation

The International Liver Cancer Association's 19th Annual Conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she spent in the educational activity.


Junior Investigator Awards

ILCA will recognize extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The awards will be given for novel and significant liver cancer research across the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or cancer patients treatment.

The investigators who submit the best clinical oral and best poster presentations and the best basic-translational oral and best poster presentations will be honored LIVE on Thursday, 20th November at the Presidential Address & Awards Ceremony at 11.30 EDT (Eastern Daylight Time). Presidential Address and Awards Ceremony.

Official Language

The official language of the conference is English. Simultaneous translation will not be provided.





THANK YOU TO OUR SPONSORS AND SUPPORTERS FOR THEIR SUPPORT

ILCA 2025 PRINCIPAL SPONSOR




ILCA 2025 PREMIUM SPONSOR



ILCA 2025 CONFERENCE SPONSORS



ILCA 2025 CONFERENCE SUPPORTERS



Sponsor of the Young Investigators Awards

SUPPORTING ORGANISATIONS



*The scientific programme is developed entirely by ILCA and remains fully independent from any external funding sources or supporting bodies



ILCA 2025 INDUSTRY PARTNERS TOGETHER FOR BETTER LIVER CANCER PATIENT TREATMENT AND CARE.

Liver cancer incidence rates are rapidly increasing across the world. And, because it is rarely detectable early, when it is most treatable, any liver cancer is difficult to cure.

Our industry partnership programme for 2025 offers healthcare companies the platform from which to support ILCA's mission and values through educational, scientific activities and events.

We offer a strategic forum for high-level dialogue between ILCA leadership and industry partners to discuss the key issues for the future of liver cancer treatment, as well as recognition of your year-round partnership support.

Guerbet | 





About ILCA

Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to liver cancer by connecting expertise from interrelated fields, research and treatment levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted exclusively to liver cancer across disciplines.

Our Mission

ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from all interrelated fields and countries and strives to welcome and incorporate individuals involved in all the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual members. ILCA actively partners with other professional associations involved in any aspect related to liver cancer research, with the objective to join efforts for the benefit of science.

Joining Our Community

We invite you to discover more about ILCA on www.ilca-online.org, as well as to connect with our expanding group of interested physicians, scientists, and allied health professionals from various fields and from around the world.

Membership to ILCA not only provides you with exclusive benefits such as reduced registration rates to our Annual Conferences, exciting networking and educational opportunities and active involvement in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research and care.

ILCA Governing Board

EXECUTIVE COMMITTEE	COUNCIL	GOVERNING BOARD ADVISORS
President: Tim Meyer, UK	Jesper Andersen, Denmark	Manon Allaire, France
Executive Secretary: Amit Singal, USA	Tim Greten, USA	Alejandro Forner, Spain
Treasurer: Valerie Chew, Singapore	Sumera I. Ilyas, USA	Federico Piñeiro, Argentina
Head of External Relations: Lorenza Rimassa, Italy	Valérie Paradis, France	Marco Sanduzzi, Spain
President Elect: Stephen Chan, Honk Kong SAR, China	Neehar Parikh, USA	
	Anjana Pillai, USA	
	David Pinato, UK	
	Gonzalo Sapisochin, Spain	
	Daniela Sia, USA	
	Carmen Wong, Hong Kong SAR, China	



ILCA AC2025 INDUSTRY SYMPOSIA



Thursday, 20th November 2025, 13.00 – 14.00

Roche Lunch Industry Symposium

Title: Redefining What's Possible: The Evolution of HCC Treatment and Care Today

Description: In this symposium, the latest data and its impact on the evolving treatment and care landscape in HCC will be discussed by our expert faculty.

Chair & Faculty: Stephen Chan, Hui-Chuan Sun, Yonghong Zhang, Maria Reig

Program	
TOPIC	PRESENTERS
Welcome and introductions	Stephen Chan (Chair)
Evolving therapeutic strategies in unresectable HCC	All faculty (Chan, Sun, Zhang, Reig)
Emerging therapeutic horizons in HCC	Stephen Chan (Chair) María Reig
Q&A and discussion	All faculty (Chan, Sun, Zhang, Reig)
Close	Stephen Chan (Chair)



Thursday, 20th November 2025, 17.45 -18.45

AstraZeneca Industry Symposium

Title: Advancing patient care for hepatobiliary cancers: emerging treatments and future outlooks

Panel: Anjana Pillai, David Tai, Chi-Leung Chiang, Chiara Braconi

Program	
TOPIC	PRESENTERS
Welcome and introductions	Anjana Pillai (Chair)
Current and future therapeutic landscape of BTC	Chiara Braconi
Patient case followed by panel discussion: Treatment considerations for advanced BTC	Presenter / moderator: David Tai All faculty participation
Exploring immunotherapy-based approaches across the HCC continuum	Chi-Leung Chiang
Panel discussion: Potential considerations for early intervention with immunotherapy in HCC	Presenter / moderator: Anjana Pillai All faculty participation
Q&A and discussion	All faculty



ILCA AC2025 INDUSTRY SYMPOSIA

Guerbet |

Friday, 21st November 2025, 08.30 – 09.30

Guerbet Industry Symposium

Title: Downstaging Strategies in HCC: Bridging the Gap to curative therapies

Panel: Prof Valérie Vilgrain, Prof Maxime Ronot, Dr. Julius Chapiro, Dr Richard Fin, Prof Kuang Ming

Program	
TOPIC	PRESENTERS
Welcome & Introduction: Understanding Stage Migration in HCC	Prof. Valérie Vilgrain
cTACE as a Gateway to Curative Intent in HCC	Prof. Maxime Ronot
Maximizing Therapeutic Impact Through Complete Tumor Resection in HCC	Prof. Kuang Ming
Immunotherapy and Locoregional Therapies: Allies in Downstaging?	Dr. Julius Chapiro & Dr. Richard Finn
Stage Migration in HCC: From BCLC to Real-World Practice (Case Discussion & Q&A)	All Speakers
Closing Remarks	Prof. Vilgrain & Dr. Chapiro



Friday, 21st November 2025, 13.15 – 14.15

Eisai Lunch Industry Symposium

Title: Navigating Complexity: Multimodal Innovations in Unresectable Hepatocellular Carcinoma (HCC)

Co-chairs: Prof Stephen Chan, Prof SUN Hui Chuan

Speakers: Assoc Prof Krittiya Korphaisarn, Prof Josep M Llovet, Prof Masatoshi Kudo

Program	
TOPIC	PRESENTERS
Current and Emerging Systemic Therapies in Unresectable Advanced HCC	Assoc Prof. Krittiya Korphaisarn
Integrated Approaches in HCC: Combining Systemic and Locoregional Strategies	Prof. Josep M Llovet
The Art of Selection: Optimizing Outcomes with Systemic and/or Locoregional Therapies	Prof. Masatoshi KUDO



JOIN THE **ILCA COMMUNITY AND
REGISTER FOR THE CONFERENCE NOW!
WE CAN'T WAIT TO SEE YOU !**

Contact us for more details:
International Liver Cancer Association (ILCA)
Avenue des arts, 47
B-1000 Brussels – Belgium

Tel: +32 (0)2 320 2531
Email: info@ilca-online.org
Website: www.ilca-online.org

